author-photo

Peter Borchmann

University of Cologne

351

Papers

8912

Citations

Citation Trend

Filter By

Papers (245) Sort By

Journal Conference Others

In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection

2021
Show All
- Source
- Cite
- Save
Citations (1)
Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (2)
Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma - feasibility of MTX-based regimens in clinical routine.

2021 European Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
PET-guided omission of radiotherapy in Hodgkin lymphoma - Authors' reply.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.

2021 The Lancet Haematology
Show All
- Source
- Cite
- Save
Citations (2)